Oxycodone IR
Sponsors
Ortho-McNeil Janssen Scientific Affairs, LLC, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Nektar Therapeutics, Medlab Clinical, Tris Pharma, Inc.
Conditions
Acute PainArthritisBack PainBack Pain With RadiationCancer Related PainJoint DiseasesLow Back PainModerate to Severe Chronic Pain
Phase 1
Phase 3
Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis
CompletedNCT00771758
Start: 2008-09-30End: 2009-12-31Updated: 2014-05-09
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
CompletedNCT00784277
Start: 2008-10-31End: 2009-07-31Updated: 2012-02-13
Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery
CompletedNCT00814580
Start: 2008-12-31End: 2010-03-31Updated: 2012-11-20
NUCYNTA (Tapentadol Immediate Release) Versus Oxycodone Immediate Release in the Treatment of Acute Low Back Pain
CompletedNCT00986180
Start: 2009-09-30End: 2010-12-31Updated: 2012-12-19
NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers
NCT04808531
Start: 2023-11-30End: 2024-06-30Target: 360Updated: 2022-04-12
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
CompletedNCT06423703
Start: 2024-07-18End: 2025-01-31Updated: 2026-01-26